Clinical Trial Update: A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze) [Phase 2]

View source ↗

Summary

A Phase II clinical trial at the University of Michigan Rogel Cancer Center is evaluating personalized de-escalation treatment for p16-positive oropharyngeal ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oropharyngeal Cancer
• Squamous Cell Carcinoma of the Oropharynx

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Oropharyngeal Cancer, Squamous Cell Carcinoma of the Oropharynx | Phase 2 | Status: RECRUITING